Hims & Hers Health Inc. is facing a class action lawsuit filed by investors who acquired the company's securities between April 29, 2025, and June 23, 2025. The lawsuit, filed in the Northern District of California, accuses the company and its top executives of violating the Securities Exchange Act of 1934. The allegations claim that Hims & Hers engaged in the deceptive promotion and sale of illegitimate versions of Novo Nordisk's Wegovy®, posing a risk to patient safety. This deceptive practice allegedly led to Novo Nordisk terminating its collaboration with Hims & Hers, resulting in a significant drop in the company's stock price by over 34%. Investors who suffered substantial losses during this period have until August 25, 2025, to seek appointment as lead plaintiff in the case.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。